Abstract
The phase 3 REGAIN study (NCT01997229) and its open-label extension (OLE; NCT02301624) evaluated eculizumab’s efficacy and safety in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (gMG). Although not approved for MG, rituximab has been used in such patients. The aim of this secondary analysis was to assess response to eculizumab in individuals with gMG previously treated with rituximab. Eculizumab is not reimbursed for neurology indications in Italy as of April 2021.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
